Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2025 / May / Neil Kelleher: The Human Proteoform Project Could Transform Healthcare / Notecards
Clinical Translational Science Keynote Interviews Trends

Neil Kelleher: The Human Proteoform Project Could Transform Healthcare

We could be 20-30 years away from inventing and integrating next-generation proteomics technologies into healthcare

05/02/2025 10 min read
article Full Article subject Summary summarize Notecard

Share

1. Proteomics holds the potential to revolutionize healthcare, enhance precision medicine, and predict and prevent diseases. 2. A structured, standardized approach to defining proteoforms through the Human Proteoform Project is crucial. 3. High-resolution reference proteomes are essential to enable next-gen proteomics. 4. Neil Kelleher envisions a future where proteomics technologies are fully integrated into healthcare systems, impacting early-stage R&D and drug development. 5. The lack of interest from major stakeholders is a primary hurdle in turning the blue-sky vision of proteomics into reality.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.